aTyr Pharma (ATYR)
(Delayed Data from NSDQ)
$1.89 USD
+0.02 (1.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $1.88 -0.01 (-0.53%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ATYR 1.89 +0.02(1.07%)
Will ATYR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ATYR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATYR
Is aTyr Pharma (ATYR) Outperforming Other Medical Stocks This Year?
ATYR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ATYR
aTyr Pharma to Participate in September Investor Conferences
Buy Rating on aTyr Pharma Anchored by Upcoming Clinical Trials and Strong Financials
RBC Capital Reaffirms Their Buy Rating on aTyr Pharma (ATYR)
Strong Buy Rating for aTyr Pharma Amid Clinical Progress and Financial Stability
Atyr Pharma: Q2 Earnings Snapshot